Efficacy, safety and mechanistic insights of pentoxifylline in major depressive disorder: a systematic review and meta-analysis of randomized controlled trials - PubMed
a day ago
- #Meta-analysis
- #Inflammation
- #Depression
- Pentoxifylline (PTX) shows significant improvement in HAM-D scores for major depressive disorder (MDD).
- PTX increases serotonin and BDNF levels while decreasing TNF-α and IL-6 levels.
- No significant difference in side effects between PTX and placebo groups.
- PTX may be an effective and safe adjuvant antidepressant for MDD.
- Study limitations suggest cautious interpretation of results.